Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities

• Published in: Cancer science Vol. 115; no. 7; pp. 2159 - 2169
• Main Authors: Wang, Ming‐Da, Xu, Xue‐Jun, Wang, Ke‐Chun, Diao, Yong‐Kang, Xu, Jia‐Hao, Gu, Li‐Hui, Yao, Lan‐Qing, Li, Chao, Lv, Guo‐Yue, Yang, Tian
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.07.2024; John Wiley and Sons Inc
• Subjects: advanced hepatocellular carcinoma; Cancer therapies; Candidates; Cell death; Chemoembolization; Chemotherapy; Clinical medicine; conversion therapy; Embolization; Gastrointestinal tract; Hepatocellular carcinoma; immune checkpoint inhibitors; Kinases; Liver cancer; locoregional treatment; Malignancy; Medical prognosis; molecular targeted therapy; Mortality; Multidisciplinary teams; Precision medicine; prognosis; resection; Review; Surgery; Tumors; Veins & arteries; advanced hepatocellular carcinoma; locoregional treatment; conversion therapy; molecular targeted therapy; immune checkpoint inhibitors; prognosis; resection

Hepatocellular carcinoma (HCC), the most prevalent malignancy of the digestive tract, is characterized by a high mortality rate and poor prognosis, primarily due to its initial diagnosis at an advanced stage that precludes any surgical intervention. Recent advancements in systemic therapies have sig...